Trial Profile

A clinical trial of EVM 201 for Cancer Related Distress

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 20 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EVM 201 (Primary)
Indications Psychotic disorders
Focus Adverse reactions

Most Recent Events

14 Nov 2024 According to an Enveric Biosciences media release, company out-licensed EVM201 Program including EB-002 Candidate to MycoMedica Life Sciences.
24 Oct 2022 According to an Enveric Biosciences media release, an Investigational New Drug (IND) application for EVM-201 is expected to be filled to the Food & Drug Administration (FDA) in the second half of 2023.
07 Apr 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com